Nektar Therapeutics

American healthcare company

NKTR Nasdaq ISIN US6402683063 SEC CIK 906709 LEI 5299005I24806IOIYE03
Follow Nektar Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $9.4M −20.4% vs same quarter last year
Net income −$55.7M −56.7% vs same quarter last year
EPS, diluted −$1.63 +12.8% vs same quarter last year
Operating cash flow −$71.9M −47.5% vs same quarter last year
Revenue by quarter
$29.2M
$10.5M
$11.2M
$11.8M
$21.8M
$10.9M
$10.1M
$9.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$1B−$500M$0$500M$1B$1.5BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$55.2M−$164M
FY24$98.4M−$119M
FY23$90.1M−$276M
FY22$92.1M−$368M
FY21$101.9M−$524M
FY20$152.9M−$444.4M
FY19$114.6M−$440.7M
FY18$1.2B$681.3M
FY17$307.7M−$96.7M
FY16$165.4M−$153.5M
FY15$230.8M−$81.2M
FY14$200.7M−$53.9M
FY13$148.9M−$162M
FY12$81.2M−$171.9M
FY11$71.5M−$134M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25100%−253.7%−296.9%
FY2468.8%−106.9%−120.9%
FY2362.5%−292.6%−306.3%
FY2276.5%−408.6%−399.8%
FY2175.6%−437.8%−514.2%
FY2087.3%−278%−290.6%
FY1981.4%−383.9%−384.5%
FY1898%57.6%57.1%
FY1790.1%−19.4%−31.4%
FY1681.7%−68.2%−92.8%
FY1585.2%−12.7%−35.2%
FY1485.8%−8.2%−26.9%
FY1374.1%−80.7%−108.8%
FY1262.5%−173.9%−211.7%
FY1169.4%−173.4%−187.4%
Free cash flowOperating cash flow minus capital expenditure
−$500M$0$500M$1BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$208.7M
FY24−$177.2M
FY23−$193.5M
FY22−$309.7M
FY21−$427.6M
FY20−$320.5M
FY19−$355M
FY18$704M
FY17−$90.1M
FY16−$123.4M
FY15−$84.3M
FY14−$152M
FY13−$42.6M
FY12−$140.3M
FY11−$123.5M
Returned to shareholdersDividends paid and shares bought back
$0$1M$2M$3MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$0
FY24$3M
FY23$0
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Nektar Therapeutics
  • Healthcare median
−600%−400%−200%0%200%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNektar TherapeuticsHealthcare median
FY25−296.9%−30.6%
FY24−120.9%−47%
FY23−306.3%−58%
FY22−399.8%−80.4%
FY21−514.2%−71.8%
FY20−290.6%−62.2%
FY19−384.5%−46.2%
FY1857.1%−49.6%
FY17−31.4%−45.9%
FY16−92.8%−36%
FY15−35.2%−37.8%
FY14−26.9%−35.5%
FY13−108.8%−37.1%
FY12−211.7%−29.1%
FY11−187.4%−27.9%